EnglishDE
Skip to main content

Prof. Dr. med.
Aristoteles Giagounidis

Facharzt für Innere Medizin
Hämatologie
Internistische Onkologie

E-Mail schreiben

Name

Giagounidis

First Name

Aristoteles

Titel

Prof. Dr. med.

Date of birth

26.11.1966

Place of birth

St. Ingbert, Germany

Nationality

German

Medical director at

Klinik für Onkologie, Hämatologie und Palliativmedizin, Marien Hospital Düsseldorf GmbH, Rochusstr. 2, 40479 Düsseldorf, Germany
phone: +49(0)211 4400-2079 / fax: +49(0)211 4400-2089

University Education

and Professional Curriculum:

1986 to1992 

Medicine at Eberhard-Karls-Universität Tübingen, Germany

1992  

Doctorate thesis: A new fruktosamine test, Universität Tübingen, Germany

08/1992-02/1993

House Officer at Withybush General Hospital,
Haverfordwest, Wales, UK

02/1993 - 08/1993

House Officer at William Harvey Hospital in Ashford, Kent, UK

1992

licence to practice medicine, Regierungspräsidium Stuttgart, Germany

10/1993-10/1999

Senior House Officer at Heinrich-Heine-Universität Düsseldorf, Germany, Klinik für Hämatologie, Onkologie und klinische Immunologie, Direktor: Prof. Dr. W. Schneider

10/1999

Board certificate in Internal Medicine („Arzt für Innere Medizin“) at Ärztekammer Nordrhein, Düsseldorf, Germany

04/2008 

Board certificate in Hematology/Oncology (Schwerpunkt Hämatologie und Onkologie) Ärztekammer Nordrhein, Düsseldorf, Germany

10/1999-08/2012

Attending at Medizinische Klinik 2, St. Johannes Hospital, Duisburg, Germany

08/2008

Habilitation at Technische Universität Dresden, Germany

since 8/2008

lecturer at the University of Dresden, Germany

since 08/2008

member of the scientific advisory board of the Aplastic Anaemia & Myelodysplastic Syndromes Foundation, Rockville/MD, USA

6/2009 -09/2012

Head of Clinical Research Department at Medizinische Klinik 2, St. Johannes Hospital, Duisburg, Germany

since 09/2012

Head of Department of Oncology, Hematology and palliative Care, Marien Hospital Düsseldorf GmbH, Düsseldorf, Germany

Research

Myelodysplastic syndromes, especially 5q-syndrome, Immune thrombocytopenia

latest GCP update

29.08.2019 / Düsseldorf

Inspections

FDA (30.11-04.11.2005)
EMEA (30.05.-02.06.2006)
Zentrales Inspektorat für Klinische Prüfungen in NRW (13.01.2010)

Study experience (example)

Indikation

EudraCT No.

Phase

Role in study

Study period

MDS

UNK

II

PI

2003-2008

MDS

UNK

III

Investigator

2000-2008

MDS

UNK

III

PI

2004 – 07/2009

MDS

UNK

III

Investigator

2003 – 2008

AML

2005-005966-35

II

PI

2006 -

MDS

2005-000454-73

III

PI

2007 -2010

Hodgkin Lymphoma

2005-005144-62

III

PI

2005-

ITP

2006-003700-18

III

PI

2007-2010

NHL

2006-001641-33

II / III

PI

2008-

MDS

2007-002532-28

II

PI

2008 – 2009

ITP

2007-006081-15

 

PI

2008-2011

MDS

2007-007258-75

 

PI

2009-2011

AML

2008-004968-40

II

PI

2009-

Multiple Myeloma

2007-003945-33

 

PI

2009-

AML

2009-010114-30

II

PI

2010-2011

MDS

2009-011513-24

III

PI

2010-

ITP

2009-010421-39

 

PI

2010-2014

sAML / MDS

2009-015512-17

I / II

PI

2010-2012

CML

2009-017775-19

III

PI

2010-2014

ITP

2010-019987-35

II

PI

2010-2013

CML

2010-024262-22

III

PI

2012-

AML

2009-009916-33

II

PI

2012-

MDS

2010-022884-36

III

PI

2011-

MDS

2012-002523-14

II

PI

2013-

CML

2012-004092-40

II

PI

2013-

AML

2013-003191-12

III

PI

2015-

CMML

2014-000200-10

III

PI

2015-

AML

2014-001233-89

III

PI

2015-

Mamma-Ca.

2014-001502-18

III

PI

2015-

MDS / AML

2015-003596-30

II

PI

2016-

CML

2014-005531-13

II

PI

2016

https://www.ncbi.nlm.nih.gov/pubmed/?term=Aristoteles+Giagounidis

1: Santini V, Valcárcel D, Platzbecker U, Komrokji RS, Cleverly AL, Lahn MM,
Janssen J, Zhao Y, Chiang A, Giagounidis A, Guba SC, Gueorguieva I, Girvan AC, da
Silva Ferreira M, Bhagat TD, Pradhan K, Steidl U, Sridharan A, Will B, Verma A.
Phase II Study of the ALK5 Inhibitor Galunisertib in Very Low-, Low-, and
Intermediate-Risk Myelodysplastic Syndromes. Clin Cancer Res. 2019 Sep 3. doi:
10.1158/1078-0432.CCR-19-1338. [Epub ahead of print] PubMed PMID: 31481511.


2: Mitsogianni M, Mitsimponas N, Haase S, Giagounidis A. Treatment of Combined
Autoimmune Neutropenia and Immune Thrombocytopenia with Methotrexate. Acta
Haematol. 2019 Jun 28:1-2. doi: 10.1159/000500872. [Epub ahead of print] PubMed
PMID: 31256147.


3: Garcia-Manero G, Almeida A, Fenaux P, Gattermann N, Giagounidis A, Goldberg
SL, Ozawa K, Weaver J, Santini V. Clinical Benefit-Risk Profile of Lenalidomide
in Patients With Lower-risk Myelodysplastic Syndromes Without del(5q): Results of
a Phase III Trial. Clin Lymphoma Myeloma Leuk. 2019 Apr;19(4):213-219.e4. doi:
10.1016/j.clml.2018.12.012. Epub 2018 Dec 21. PubMed PMID: 30770308.


4: Hüttmann A, Rekowski J, Müller SP, Hertenstein B, Franzius C, Mesters R,
Weckesser M, Kroschinsky F, Kotzerke J, Ganser A, Bengel FM, La Rosée P,
Freesmeyer M, Höffkes HG, Hertel A, Behringer D, Prange-Krex G, Griesshammer M,
Holzinger J, Wilop S, Krohn T, Raghavachar A, Maschmeyer G, Brink I, Schroers R,
Gaska T, Bernhard H, Giagounidis A, Schütte J, Dienst A, Hautzel H, Naumann R,
Klein A, Hahn D, Pöpperl G, Grube M, Marienhagen J, Schwarzer A, Kurch L, Höhler
T, Steiniger H, Nückel H, Südhoff T, Römer W, Brinkmann M, Ose C, Alashkar F,
Schmitz C, Dürig J, Hoelzer D, Jöckel KH, Klapper W, Dührsen U. Six versus eight
doses of rituximab in patients with aggressive B cell lymphoma receiving six
cycles of CHOP: results from the "Positron Emission Tomography-Guided Therapy of
Aggressive Non-Hodgkin Lymphomas" (PETAL) trial. Ann Hematol. 2019
Apr;98(4):897-907. doi: 10.1007/s00277-018-3578-0. Epub 2019 Jan 4. PubMed PMID:
30610279.


5: Platzbecker U, Fenaux P, Adès L, Giagounidis A, Santini V, van de Loosdrecht
AA, Bowen D, de Witte T, Garcia-Manero G, Hellström-Lindberg E, Germing U,
Stauder R, Malcovati L, Sekeres MA, Steensma DP, Gloaguen S. Proposals for
revised IWG 2018 hematological response criteria in patients with MDS included in
clinical trials. Blood. 2019 Mar 7;133(10):1020-1030. doi:
10.1182/blood-2018-06-857102. Epub 2018 Nov 7. PubMed PMID: 30404811.


6: Sekeres MA, Swern AS, Giagounidis A, List AF, Selleslag D, Mittelman M,
Schlegelberger B, Göhring G, Li JS, Sugrue MM, Fenaux P. The impact of
lenalidomide exposure on response and outcomes in patients with lower-risk
myelodysplastic syndromes and del(5q). Blood Cancer J. 2018 Sep 21;8(10):90. doi:
10.1038/s41408-018-0126-z. PubMed PMID: 30291223; PubMed Central PMCID:
PMC6173782.


7: Schanz J, Solé F, Mallo M, Luño E, Cervera J, Granada I, Hildebrandt B, Slovak
ML, Ohyashiki K, Fonatsch C, Pfeilstöcker M, Nösslinger T, Valent P, Giagounidis
A, Aul C, Lübbert M, Stauder R, Krieger O, Le Beau MM, Bennett JM, Greenberg P,
Germing U, Haase D. Clonal architecture in patients with myelodysplastic
syndromes and double or minor complex abnormalities: Detailed analysis of clonal
composition, involved abnormalities, and prognostic significance. Genes
Chromosomes Cancer. 2018 Nov;57(11):547-556. doi: 10.1002/gcc.22667. Epub 2018
Sep 24. PubMed PMID: 30248204.


8: Morschhauser F, Fowler NH, Feugier P, Bouabdallah R, Tilly H, Palomba ML,
Fruchart C, Libby EN, Casasnovas RO, Flinn IW, Haioun C, Maisonneuve H, Ysebaert
L, Bartlett NL, Bouabdallah K, Brice P, Ribrag V, Daguindau N, Le Gouill S, Pica
GM, Martin Garcia-Sancho A, López-Guillermo A, Larouche JF, Ando K, Gomes da
Silva M, André M, Zachée P, Sehn LH, Tobinai K, Cartron G, Liu D, Wang J, Xerri
L, Salles GA; RELEVANCE Trial Investigators. Rituximab plus Lenalidomide in
Advanced Untreated Follicular Lymphoma. N Engl J Med. 2018 Sep 6;379(10):934-947.
doi: 10.1056/NEJMoa1805104. PubMed PMID: 30184451.


9: Pellagatti A, Armstrong RN, Steeples V, Sharma E, Repapi E, Singh S, Sanchi A,
Radujkovic A, Horn P, Dolatshad H, Roy S, Broxholme J, Lockstone H, Taylor S,
Giagounidis A, Vyas P, Schuh A, Hamblin A, Papaemmanuil E, Killick S, Malcovati
L, Hennrich ML, Gavin AC, Ho AD, Luft T, Hellström-Lindberg E, Cazzola M, Smith
CWJ, Smith S, Boultwood J. Impact of spliceosome mutations on RNA splicing in
myelodysplasia: dysregulated genes/pathways and clinical associations. Blood.
2018 Sep 20;132(12):1225-1240. doi: 10.1182/blood-2018-04-843771. Epub 2018 Jun
21. PubMed PMID: 29930011; PubMed Central PMCID: PMC6172604.


10: Fenaux P, Santini V, Spiriti MAA, Giagounidis A, Schlag R, Radinoff A,
Gercheva-Kyuchukova L, Anagnostopoulos A, Oliva EN, Symeonidis A, Berger MH,
Götze KS, Potamianou A, Haralampiev H, Wapenaar R, Milionis I, Platzbecker U. A
phase 3 randomized, placebo-controlled study assessing the efficacy and safety of
epoetin-α in anemic patients with low-risk MDS. Leukemia. 2018
Dec;32(12):2648-2658. doi: 10.1038/s41375-018-0118-9. Epub 2018 Mar 30. PubMed
PMID: 29895954; PubMed Central PMCID: PMC6286328.


11: Dührsen U, Müller S, Hertenstein B, Thomssen H, Kotzerke J, Mesters R, Berdel
WE, Franzius C, Kroschinsky F, Weckesser M, Kofahl-Krause D, Bengel FM, Dürig J,
Matschke J, Schmitz C, Pöppel T, Ose C, Brinkmann M, La Rosée P, Freesmeyer M,
Hertel A, Höffkes HG, Behringer D, Prange-Krex G, Wilop S, Krohn T, Holzinger J,
Griesshammer M, Giagounidis A, Raghavachar A, Maschmeyer G, Brink I, Bernhard H,
Haberkorn U, Gaska T, Kurch L, van Assema DME, Klapper W, Hoelzer D, Geworski L,
Jöckel KH, Scherag A, Bockisch A, Rekowski J, Hüttmann A; PETAL Trial
Investigators. Positron Emission Tomography-Guided Therapy of Aggressive
Non-Hodgkin Lymphomas (PETAL): A Multicenter, Randomized Phase III Trial. J Clin
Oncol. 2018 Jul 10;36(20):2024-2034. doi: 10.1200/JCO.2017.76.8093. Epub 2018 May
11. PubMed PMID: 29750632.


12: Mitsogianni M, Mitsimponas N, Crespo F, Hartmann KA, Klosterhalfen B, Haase
S, Giagounidis A. Concomitant Non-Small Cell Lung Cancer and Hairy Cell Leukemia
in a Patient Harboring BRAF-V600E Mutation in Both Tissues: A Case Report. Case
Rep Oncol. 2018 Feb 14;11(1):109-113. doi: 10.1159/000486640. eCollection 2018
Jan-Apr. PubMed PMID: 29606948; PubMed Central PMCID: PMC5869534.


13: Santini V, Almeida A, Giagounidis A, Platzbecker U, Buckstein R, Beach CL,
Guo S, Altincatal A, Wu C, Fenaux P. The Effect of Lenalidomide on Health-Related
Quality of Life in Patients With Lower-Risk Non-del(5q) Myelodysplastic
Syndromes: Results From the MDS-005 Study. Clin Lymphoma Myeloma Leuk. 2018
Feb;18(2):136-144.e7. doi: 10.1016/j.clml.2017.12.004. Epub 2017 Dec 30. PubMed
PMID: 29429612.


14: Kantarjian HM, Fenaux P, Sekeres MA, Szer J, Platzbecker U, Kuendgen A,
Gaidano G, Wiktor-Jedrzejczak W, Carpenter N, Mehta B, Franklin J, Giagounidis A.
Long-term follow-up for up to 5 years on the risk of leukaemic progression in
thrombocytopenic patients with lower-risk myelodysplastic syndromes treated with
romiplostim or placebo in a randomised double-blind trial. Lancet Haematol. 2018
Mar;5(3):e117-e126. doi: 10.1016/S2352-3026(18)30016-4. Epub 2018 Jan 26. PubMed
PMID: 29396092.


15: Giagounidis A. Current treatment algorithm for the management of lower-risk
MDS. Hematology Am Soc Hematol Educ Program. 2017 Dec 8;2017(1):453-459. doi:
10.1182/asheducation-2017.1.453. Review. PubMed PMID: 29222293; PubMed Central
PMCID: PMC6142548.


16: Valent P, Orazi A, Steensma DP, Ebert BL, Haase D, Malcovati L, van de
Loosdrecht AA, Haferlach T, Westers TM, Wells DA, Giagounidis A, Loken M, Orfao
A, Lübbert M, Ganser A, Hofmann WK, Ogata K, Schanz J, Béné MC, Hoermann G, Sperr
WR, Sotlar K, Bettelheim P, Stauder R, Pfeilstöcker M, Horny HP, Germing U,
Greenberg P, Bennett JM. Proposed minimal diagnostic criteria for myelodysplastic
syndromes (MDS) and potential pre-MDS conditions. Oncotarget. 2017 Jul
5;8(43):73483-73500. doi: 10.18632/oncotarget.19008. eCollection 2017 Sep 26.
PubMed PMID: 29088721; PubMed Central PMCID: PMC5650276.


17: Metzelder SK, Schroeder T, Lübbert M, Ditschkowski M, Götze K, Scholl S,
Meyer RG, Dreger P, Basara N, Fey MF, Salih HR, Finck A, Pabst T, Giagounidis A,
Kobbe G, Wollmer E, Finke J, Neubauer A, Burchert A. Long-term survival of
sorafenib-treated FLT3-ITD-positive acute myeloid leukaemia patients
relapsing after allogeneic stem cell transplantation. Eur J Cancer. 2017
Nov;86:233-239. doi: 10.1016/j.ejca.2017.09.016. Epub 2017 Oct 18. PubMed PMID:
29055209.


18: Platzbecker U, Germing U, Götze KS, Kiewe P, Mayer K, Chromik J, Radsak M,
Wolff T, Zhang X, Laadem A, Sherman ML, Attie KM, Giagounidis A. Luspatercept for
the treatment of anaemia in patients with lower-risk myelodysplastic syndromes
(PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term
extension study. Lancet Oncol. 2017 Oct;18(10):1338-1347. doi:
10.1016/S1470-2045(17)30615-0. Epub 2017 Sep 1. Erratum in: Lancet Oncol. 2017
Oct;18(10):e562. PubMed PMID: 28870615.


19: Mitsimponas N, Mitsogianni M, Crespo F, Hartmann KA, Diederich S,
Klosterhalfen B, Giagounidis A. Isolated Splenic Metastasis from Non-Small-Cell
Lung Cancer: A Case Report and Review of the Literature. Case Rep Oncol. 2017 Jul
11;10(2):638-643. doi: 10.1159/000478002. eCollection 2017 May-Aug. PubMed PMID:
28868024; PubMed Central PMCID: PMC5567076.


20: Fenaux P, Giagounidis A, Selleslag D, Beyne-Rauzy O, Mittelman M, Muus P,
Nimer SD, Hellström-Lindberg E, Powell BL, Guerci-Bresler A, Sekeres MA, Deeg HJ,
Del Cañizo C, Greenberg PL, Shammo JM, Skikne B, Yu X, List AF. Clinical
characteristics and outcomes according to age in lenalidomide-treated patients
with RBC transfusion-dependent lower-risk MDS and del(5q). J Hematol Oncol. 2017
Jun 26;10(1):131. doi: 10.1186/s13045-017-0491-2. PubMed PMID: 28651604; PubMed
Central PMCID: PMC5485496.


21: Jann JC, Nowak D, Nolte F, Fey S, Nowak V, Obländer J, Pressler J, Palme I,
Xanthopoulos C, Fabarius A, Platzbecker U, Giagounidis A, Götze K, Letsch A,
Haase D, Schlenk R, Bug G, Lübbert M, Ganser A, Germing U, Haferlach C, Hofmann
WK, Mossner M. Accurate quantification of chromosomal lesions via short tandem
repeat analysis using minimal amounts of DNA. J Med Genet. 2017
Sep;54(9):640-650. doi: 10.1136/jmedgenet-2017-104528. Epub 2017 Jun 9. PubMed
PMID: 28600436; PubMed Central PMCID: PMC5574397.


22: Braulke F, Schulz X, Germing U, Schuler E, Platzbecker U, Nolte F, Hofmann
WK, Giagounidis A, Götze K, Lübbert M, Schlenk RF, Schanz J, Bacher U, Ganser A,
Büsche G, Letsch A, Schafhausen P, Bug G, Brümmendorf TH, Haas R, Trümper L,
Shirneshan K, Haase D. Peripheral blood cytogenetics allows treatment monitoring
and early identification of treatment failure to lenalidomide in MDS patients:
results of the LE-MON-5 trial. Ann Hematol. 2017 Jun;96(6):887-894. doi:
10.1007/s00277-017-2983-0. Epub 2017 Apr 3. PubMed PMID: 28374162.


23: Strupp C, Nachtkamp K, Hildebrandt B, Giagounidis A, Haas R, Gattermann N,
Bennett JM, Aul C, Germing U. New proposals of the WHO working group (2016) for
the diagnosis of myelodysplastic syndromes (MDS): Characteristics of refined MDS
types. Leuk Res. 2017 Jun;57:78-84. doi: 10.1016/j.leukres.2017.02.008. Epub 2017
Feb 27. PubMed PMID: 28324772.


24: Santini V, Almeida A, Giagounidis A, Gröpper S, Jonasova A, Vey N, Mufti GJ,
Buckstein R, Mittelman M, Platzbecker U, Shpilberg O, Ram R, Del Cañizo C,
Gattermann N, Ozawa K, Risueño A, MacBeth KJ, Zhong J, Séguy F, Hoenekopp A,
Beach CL, Fenaux P. Randomized Phase III Study of Lenalidomide Versus Placebo in
RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic
Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents.
J Clin Oncol. 2016 Sep 1;34(25):2988-96. doi: 10.1200/JCO.2015.66.0118. Epub 2016
Jun 27. PubMed PMID: 27354480.


25: Groepper S, Schlue J, Haferlach C, Giagounidis A. Transfusion Independency
and Histological Remission in a Patient with Advanced Primary Myelofibrosis
Receiving Iron-Chelation Therapy with Deferasirox. Oncol Res Treat.
2016;39(6):384-7. doi: 10.1159/000446029. Epub 2016 May 25. PubMed PMID:
27260366.


26: Garcia-Manero G, Almeida A, Giagounidis A, Platzbecker U, Garcia R, Voso MT,
Larsen SR, Valcarcel D, Silverman LR, Skikne B, Santini V. Design and rationale
of the QUAZAR Lower-Risk MDS (AZA-MDS-003) trial: a randomized phase 3 study of
CC-486 (oral azacitidine) plus best supportive care vs placebo plus best
supportive care in patients with IPSS lower-risk myelodysplastic syndromes and
poor prognosis due to red blood cell transfusion-dependent anemia and
thrombocytopenia. BMC Hematol. 2016 May 3;16:12. doi: 10.1186/s12878-016-0049-5.
eCollection 2016. PubMed PMID: 27148452; PubMed Central PMCID: PMC4855808.


27: Mossner M, Jann JC, Nowak D, Platzbecker U, Giagounidis A, Götze K, Letsch A,
Haase D, Shirneshan K, Braulke F, Schlenk RF, Haferlach T, Schafhausen P, Bug G,
Lübbert M, Ganser A, Büsche G, Schuler E, Nowak V, Pressler J, Obländer J, Fey S,
Müller N, Lauinger-Lörsch E, Metzgeroth G, Weiß C, Hofmann WK, Germing U, Nolte
F. Prevalence, clonal dynamics and clinical impact of TP53 mutations in patients
with myelodysplastic syndrome with isolated deletion (5q) treated with
lenalidomide: results from a prospective multicenter study of the german MDS
study group (GMDS). Leukemia. 2016 Sep;30(9):1956-9. doi: 10.1038/leu.2016.111.
Epub 2016 May 2. PubMed PMID: 27133825.


28: Nachtkamp K, Stark R, Strupp C, Kündgen A, Giagounidis A, Aul C, Hildebrandt
B, Haas R, Gattermann N, Germing U. Causes of death in 2877 patients with
myelodysplastic syndromes. Ann Hematol. 2016 May;95(6):937-44. doi:
10.1007/s00277-016-2649-3. Epub 2016 Mar 30. PubMed PMID: 27025507.


29: Borthakur G, Popplewell L, Boyiadzis M, Foran J, Platzbecker U, Vey N, Walter
RB, Olin R, Raza A, Giagounidis A, Al-Kali A, Jabbour E, Kadia T, Garcia-Manero
G, Bauman JW, Wu Y, Liu Y, Schramek D, Cox DS, Wissel P, Kantarjian H. Activity
of the oral mitogen-activated protein kinase kinase inhibitor trametinib in
RAS-mutant relapsed or refractory myeloid malignancies. Cancer. 2016 Jun
15;122(12):1871-9. doi: 10.1002/cncr.29986. Epub 2016 Mar 18. Erratum in: Cancer.
2016 Oct 15;122(20):3246. PubMed PMID: 26990290; PubMed Central PMCID:
PMC5779863.


30: Kossak-Roth U, Saußele S, Aul C, Büchner T, Döhner H, Dugas M, Ehninger G,
Ganser A, Giagounidis A, Gökbuget N, Griesshammer M, Hasford J, Heuser M,
Hiddemann W, Hochhaus A, Hoelzer D, Niederwieser D, Reiter A, Röllig C, Hehlmann
R. [Leukemia research in Germany: the Competence Network Acute and Chronic
Leukemias]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2016
Apr;59(4):444-53. doi: 10.1007/s00103-016-2315-x. Review. German. PubMed PMID:
26979719.


31: Büchner T, Krug UO, Peter Gale R, Heinecke A, Sauerland MC, Haferlach C,
Schnittger S, Haferlach T, Müller-Tidow C, Stelljes M, Mesters RM, Serve HL,
Braess J, Spiekermann K, Staib P, Grüneisen A, Reichle A, Balleisen L,
Eimermacher H, Giagounidis A, Rasche H, Lengfelder E, Görlich D, Faldum A, Köpcke
W, Hehlmann R, Wörmann BJ, Berdel WE, Hiddemann W. Age, not therapy intensity,
determines outcomes of adults with acute myeloid leukemia. Leukemia. 2016
Aug;30(8):1781-4. doi: 10.1038/leu.2016.54. Epub 2016 Mar 11. PubMed PMID:
26965440.


32: Buesche G, Teoman H, Giagounidis A, Göhring G, Schlegelberger B, Ganser A,
Aul C, Kreipe HH. Impaired formation of erythroblastic islands is associated with
erythroid failure and poor prognosis in a significant proportion of patients with
myelodysplastic syndromes. Haematologica. 2016 May;101(5):e177-81. doi:
10.3324/haematol.2015.129015. Epub 2016 Mar 4. PubMed PMID: 26944473; PubMed
Central PMCID: PMC5004355.


33: Krug U, Berdel WE, Gale RP, Haferlach C, Schnittger S, Müller-Tidow C, Braess
J, Spiekermann K, Staib P, Beelen D, Serve H, Schliemann C, Stelljes M, Balleisen
L, Maschmeyer G, Grüneisen A, Eimermacher H, Giagounidis A, Rasche H, Hehlmann R,
Lengfelder E, Thiel E, Reichle A, Aul C, Ludwig WD, Kern W, Haferlach T, Köpcke
W, Görlich D, Sauerland MC, Heinecke A, Wörmann BJ, Hiddemann W, Büchner T.
Increasing intensity of therapies assigned at diagnosis does not improve survival
of adults with acute myeloid leukemia. Leukemia. 2016 Jun;30(6):1230-6. doi:
10.1038/leu.2016.25. Epub 2016 Feb 9. PubMed PMID: 26859081.


34: Platzbecker U, Wong RS, Verma A, Abboud C, Araujo S, Chiou TJ, Feigert J, Yeh
SP, Götze K, Gorin NC, Greenberg P, Kambhampati S, Kim YJ, Lee JH, Lyons R,
Ruggeri M, Santini V, Cheng G, Jang JH, Chen CY, Johnson B, Bennett J, Mannino F,
Kamel YM, Stone N, Dougherty S, Chan G, Giagounidis A. Safety and tolerability of
eltrombopag versus placebo for treatment of thrombocytopenia in patients with
advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre,
randomised, placebo-controlled, double-blind, phase 1/2 trial. Lancet Haematol.
2015 Oct;2(10):e417-26. doi: 10.1016/S2352-3026(15)00149-0. Epub 2015 Oct 1.
PubMed PMID: 26686043.


35: Schuler E, Giagounidis A, Haase D, Shirneshan K, Büsche G, Platzbecker U,
Nolte F, Götze K, Schlenk RF, Ganser A, Letsch A, Braulke F, Lübbert M, Bug G,
Schafhausen P, Bacher U, Gattermann N, Wulfert M, Haas R, Germing U. Results of a
multicenter prospective phase II trial investigating the safety and efficacy of
lenalidomide in patients with myelodysplastic syndromes with isolated del(5q)
(LE-MON 5). Leukemia. 2016 Jul;30(7):1580-2. doi: 10.1038/leu.2015.340. Epub 2015
Dec 15. PubMed PMID: 26668126.


36: List AF, Bennett JM, Sekeres MA, Skikne B, Fu T, Shammo JM, Nimer SD, Knight
RD, Giagounidis A. Extended survival and reduced risk of AML progression in
erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS.
Leukemia. 2015 Dec;29(12):2452. doi: 10.1038/leu.2015.312. PubMed PMID: 26648407.


37: Lübbert M, Suciu S, Hagemeijer A, Rüter B, Platzbecker U, Giagounidis A,
Selleslag D, Labar B, Germing U, Salih HR, Muus P, Pflüger KH, Schaefer HE,
Bogatyreva L, Aul C, de Witte T, Ganser A, Becker H, Huls G, van der Helm L,
Vellenga E, Baron F, Marie JP, Wijermans PW; EORTC Leukemia Group and the German
MDS Study Group. Decitabine improves progression-free survival in older high-risk
MDS patients with multiple autosomal monosomies: results of a subgroup analysis
of the randomized phase III study 06011 of the EORTC Leukemia Cooperative Group
and German MDS Study Group. Ann Hematol. 2016 Jan;95(2):191-9. doi:
10.1007/s00277-015-2547-0. Epub 2015 Nov 23. PubMed PMID: 26596971.


38: Röllig C, Serve H, Hüttmann A, Noppeney R, Müller-Tidow C, Krug U, Baldus CD,
Brandts CH, Kunzmann V, Einsele H, Krämer A, Schäfer-Eckart K, Neubauer A,
Burchert A, Giagounidis A, Krause SW, Mackensen A, Aulitzky W, Herbst R, Hänel M,
Kiani A, Frickhofen N, Kullmer J, Kaiser U, Link H, Geer T, Reichle A, Junghanß
C, Repp R, Heits F, Dürk H, Hase J, Klut IM, Illmer T, Bornhäuser M, Schaich M,
Parmentier S, Görner M, Thiede C, von Bonin M, Schetelig J, Kramer M, Berdel WE,
Ehninger G; Study Alliance Leukaemia. Addition of sorafenib versus placebo to
standard therapy in patients aged 60 years or younger with newly diagnosed acute
myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial.
Lancet Oncol. 2015 Dec;16(16):1691-9. doi: 10.1016/S1470-2045(15)00362-9. Epub
2015 Nov 6. PubMed PMID: 26549589.


39: Müller-Tidow C, Tschanter P, Röllig C, Thiede C, Koschmieder A, Stelljes M,
Koschmieder S, Dugas M, Gerss J, Butterfaß-Bahloul T, Wagner R, Eveslage M, Thiem
U, Krause SW, Kaiser U, Kunzmann V, Steffen B, Noppeney R, Herr W, Baldus CD,
Schmitz N, Götze K, Reichle A, Kaufmann M, Neubauer A, Schäfer-Eckart K, Hänel M,
Peceny R, Frickhofen N, Kiehl M, Giagounidis A, Görner M, Repp R, Link H, Kiani
A, Naumann R, Brümmendorf TH, Serve H, Ehninger G, Berdel WE, Krug U; Study
Alliance Leukemia Group. Azacitidine in combination with intensive induction
chemotherapy in older patients with acute myeloid leukemia: The AML-AZA trial of
the Study Alliance Leukemia. Leukemia. 2016 Mar;30(3):555-61. doi:
10.1038/leu.2015.306. Epub 2015 Nov 2. PubMed PMID: 26522083.


40: Beier F, Masouleh BK, Buesche G, Ventura Ferreira MS, Schneider RK, Ziegler
P, Wilop S, Vankann L, Gattermann N, Platzbecker U, Giagounidis A, Götze KS,
Nolte F, Hofmann WK, Haase D, Kreipe H, Panse J, Blasco MA, Germing U,
Brümmendorf TH. Telomere dynamics in patients with del (5q) MDS before and under
treatment with lenalidomide. Leuk Res. 2015 Sep 21. pii: S0145-2126(15)30380-5.
doi: 10.1016/j.leukres.2015.09.003. [Epub ahead of print] PubMed PMID: 26427727.


41: Becker H, Suciu S, Rüter BH, Platzbecker U, Giagounidis A, Selleslag D, Labar
B, Germing U, Salih HR, Muus P, Pflüger KH, Hagemeijer A, Schaefer HE, Fiaccadori
V, Baron F, Ganser A, Aul C, de Witte T, Wijermans PW, Lübbert M. Decitabine
versus best supportive care in older patients with refractory anemia with excess
blasts in transformation (RAEBt) - results of a subgroup analysis of the
randomized phase III study 06011 of the EORTC Leukemia Cooperative Group and
German MDS Study Group (GMDSSG). Ann Hematol. 2015 Dec;94(12):2003-13. doi:
10.1007/s00277-015-2489-6. Epub 2015 Sep 24. PubMed PMID: 26400023.


42: Braulke F, Müller-Thomas C, Götze K, Platzbecker U, Germing U, Hofmann WK,
Giagounidis AA, Lübbert M, Greenberg PL, Bennett JM, Solé F, Slovak ML, Ohyashiki
K, Le Beau MM, Tüchler H, Pfeilstöcker M, Hildebrandt B, Aul C, Stauder R, Valent
P, Fonatsch C, Bacher U, Trümper L, Haase D, Schanz J. Frequency of del(12p) is
commonly underestimated in myelodysplastic syndromes: Results from a German
diagnostic study in comparison with an international control group. Genes
Chromosomes Cancer. 2015 Dec;54(12):809-17. doi: 10.1002/gcc.22292. Epub 2015 Sep
10. PubMed PMID: 26355708.


43: Giagounidis A. Where Does Lenalidomide Fit in Non-del(5q) MDS? Curr Hematol
Malig Rep. 2015 Sep;10(3):303-8. doi: 10.1007/s11899-015-0275-0. Review. PubMed
PMID: 26169489.


44: Haaß W, Kleiner H, Weiß C, Haferlach C, Schlegelberger B, Müller MC, Hehlmann
R, Hofmann WK, Fabarius A, Seifarth W; Schweizerische Arbeitsgemeinschaft für
Klinische Krebsforschung; German CML Study Group. Clonal Evolution and Blast
Crisis Correlate with Enhanced Proteolytic Activity of Separase in BCR-ABL b3a2
Fusion Type CML under Imatinib Therapy. PLoS One. 2015 Jun 18;10(6):e0129648.
doi: 10.1371/journal.pone.0129648. eCollection 2015. PubMed PMID: 26087013;
PubMed Central PMCID: PMC4472749.


45: Bello E, Pellagatti A, Shaw J, Mecucci C, Kušec R, Killick S, Giagounidis A,
Raynaud S, Calasanz MJ, Fenaux P, Boultwood J. CSNK1A1 mutations and gene
expression analysis in myelodysplastic syndromes with del(5q). Br J Haematol.
2015 Oct;171(2):210-214. doi: 10.1111/bjh.13563. Epub 2015 Jun 18. PubMed PMID:
26085061; PubMed Central PMCID: PMC4744770.


46: Neukirchen J, Nachtkamp K, Schemenau J, Aul C, Giagounidis A, Strupp C,
Kuendgen A, Kobbe G, Haas R, Germing U. Change of prognosis of patients with
myelodysplastic syndromes during the last 30 years. Leuk Res. 2015
Jul;39(7):679-83. doi: 10.1016/j.leukres.2015.04.001. Epub 2015 Apr 15. PubMed
PMID: 25929166.


47: Gerstung M, Pellagatti A, Malcovati L, Giagounidis A, Porta MG, Jädersten M,
Dolatshad H, Verma A, Cross NC, Vyas P, Killick S, Hellström-Lindberg E, Cazzola
M, Papaemmanuil E, Campbell PJ, Boultwood J. Combining gene mutation with gene
expression data improves outcome prediction in myelodysplastic syndromes. Nat
Commun. 2015 Jan 9;6:5901. doi: 10.1038/ncomms6901. PubMed PMID: 25574665; PubMed
Central PMCID: PMC4338540.


48: Braulke F, Platzbecker U, Müller-Thomas C, Götze K, Germing U, Brümmendorf
TH, Nolte F, Hofmann WK, Giagounidis AA, Lübbert M, Greenberg PL, Bennett JM,
Solé F, Mallo M, Slovak ML, Ohyashiki K, Le Beau MM, Tüchler H, Pfeilstöcker M,
Nösslinger T, Hildebrandt B, Shirneshan K, Aul C, Stauder R, Sperr WR, Valent P,
Fonatsch C, Trümper L, Haase D, Schanz J. Validation of cytogenetic risk groups
according to International Prognostic Scoring Systems by peripheral blood
CD34+FISH: results from a German diagnostic study in comparison with an
international control group. Haematologica. 2015 Feb;100(2):205-13. doi:
10.3324/haematol.2014.110452. Epub 2014 Oct 24. PubMed PMID: 25344522; PubMed
Central PMCID: PMC4803133.


49: Platzbecker U, Sekeres MA, Kantarjian H, Giagounidis A, Mufti GJ, Jia C, Yang
AS, Fenaux P. Relationship of different platelet response criteria and patient
outcomes in a romiplostim myelodysplastic syndromes trial. Leukemia. 2014
Dec;28(12):2418-21. doi: 10.1038/leu.2014.253. Epub 2014 Sep 2. PubMed PMID:
25179731; PubMed Central PMCID: PMC4274610.


50: Selleslag D, Bird R, Altomare I, Giagounidis A, Janssens A, Pabinger I,
Pullarkat V, Wei H, Kreuzbauer G. Impact of self-administration of romiplostim by
patients with chronic immune thrombocytopenia compared with administration by a
healthcare provider. Eur J Haematol. 2015 Feb;94(2):169-76. doi:
10.1111/ejh.12415. Epub 2014 Aug 8. PubMed PMID: 25039799.


51: Sekeres MA, Giagounidis A, Kantarjian H, Mufti GJ, Fenaux P, Jia C, Yang AS,
Platzbecker U. Development and validation of a model to predict platelet response
to romiplostim in patients with lower-risk myelodysplastic syndromes. Br J
Haematol. 2014 Nov;167(3):337-45. doi: 10.1111/bjh.13037. Epub 2014 Jul 14.
PubMed PMID: 25039607.


52: Giagounidis A, Mufti GJ, Mittelman M, Sanz G, Platzbecker U, Muus P,
Selleslag D, Beyne-Rauzy O, te Boekhorst P, del Cañizo C, Guerci-Bresler A,
Nilsson L, Lübbert M, Quesnel B, Ganser A, Bowen D, Schlegelberger B, Göhring G,
Fu T, Benettaib B, Hellström-Lindberg E, Fenaux P. Outcomes in RBC
transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic
syndromes with isolated deletion 5q treated with lenalidomide: a subset analysis
from the MDS-004 study. Eur J Haematol. 2014 Nov;93(5):429-38. doi:
10.1111/ejh.12380. Epub 2014 Jun 9. PubMed PMID: 24813620; PubMed Central PMCID:
PMC4232868.


53: Giagounidis A, Mufti GJ, Fenaux P, Sekeres MA, Szer J, Platzbecker U,
Kuendgen A, Gaidano G, Wiktor-Jedrzejczak W, Hu K, Woodard P, Yang AS, Kantarjian
HM. Results of a randomized, double-blind study of romiplostim versus placebo in
patients with low/intermediate-1-risk myelodysplastic syndrome and
thrombocytopenia. Cancer. 2014 Jun 15;120(12):1838-46. doi: 10.1002/cncr.28663.
Epub 2014 Apr 4. PubMed PMID: 24706489; PubMed Central PMCID: PMC4298760.


54: Saft L, Karimi M, Ghaderi M, Matolcsy A, Mufti GJ, Kulasekararaj A, Göhring
G, Giagounidis A, Selleslag D, Muus P, Sanz G, Mittelman M, Bowen D, Porwit A, Fu
T, Backstrom J, Fenaux P, MacBeth KJ, Hellström-Lindberg E. p53 protein
expression independently predicts outcome in patients with lower-risk
myelodysplastic syndromes with del(5q). Haematologica. 2014 Jun;99(6):1041-9.
doi: 10.3324/haematol.2013.098103. Epub 2014 Mar 28. PubMed PMID: 24682512;
PubMed Central PMCID: PMC4040908.


55: Proetel U, Pletsch N, Lauseker M, Müller MC, Hanfstein B, Krause SW, Kalmanti
L, Schreiber A, Heim D, Baerlocher GM, Hofmann WK, Lange E, Einsele H, Wernli M,
Kremers S, Schlag R, Müller L, Hänel M, Link H, Hertenstein B, Pfirrman M,
Hochhaus A, Hasford J, Hehlmann R, Saußele S; German Chronic Myeloid Leukemia
Study Group; Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung
(SAKK). Older patients with chronic myeloid leukemia (≥65 years) profit more from
higher imatinib doses than younger patients: a subanalysis of the randomized
CML-Study IV. Ann Hematol. 2014 Jul;93(7):1167-76. PubMed PMID: 24658964; PubMed
Central PMCID: PMC4050299.


56: Matzdorff A, Eberl W, Giagounidis A, Imbach P, Pabinger I, Wörmann B. [Immune
thrombocytopenia -- onkopedic guidelines update: recommendations of a joint
working group of the DGHO, ÖGHO, SGH + SSH and GPOH]. Oncol Res Treat. 2014;37
Suppl 2:6-25. doi: 10.1159/000356910. German. PubMed PMID: 24613966.


57: Giagounidis A, Haase D. Morphology, cytogenetics and classification of MDS.
Best Pract Res Clin Haematol. 2013 Dec;26(4):337-53. doi:
10.1016/j.beha.2013.09.004. Epub 2013 Oct 1. Review. PubMed PMID: 24507811.


58: Neukirchen J, Lauseker M, Blum S, Giagounidis A, Lübbert M, Martino S,
Siragusa S, Schlenk RF, Platzbecker U, Hofmann WK, Götze K, Palumbo GA, Magrin S,
Kündgen A, Aul C, Hildebrandt B, Hasford J, Kobbe G, Haas R, Germing U.
Validation of the revised international prognostic scoring system (IPSS-R) in
patients with myelodysplastic syndrome: a multicenter study. Leuk Res. 2014
Jan;38(1):57-64. doi: 10.1016/j.leukres.2013.10.013. Epub 2013 Oct 26. PubMed
PMID: 24238640.


59: Platzbecker U, Al-Ali HK, Gattermann N, Haase D, Janzen V, Krauter J, Götze
K, Schlenk R, Nolte F, Letsch A, Ottmann OG, Kündgen A, Lübbert M, Germing U,
Wermke M, Reinhard H, Weiss C, Lieder K, Ehninger G, Leismann O, Giagounidis A.
Phase 2 study of oral panobinostat (LBH589) with or without erythropoietin in
heavily transfusion-dependent IPSS low or int-1 MDS patients. Leukemia. 2014
Mar;28(3):696-8. doi: 10.1038/leu.2013.325. Epub 2013 Nov 4. PubMed PMID:
24186004.


60: List AF, Bennett JM, Sekeres MA, Skikne B, Fu T, Shammo JM, Nimer SD, Knight
RD, Giagounidis A; MDS-003 Study Investigators. Extended survival and reduced
risk of AML progression in erythroid-responsive lenalidomide-treated patients
with lower-risk del(5q) MDS. Leukemia. 2014 May;28(5):1033-40. doi:
10.1038/leu.2013.305. Epub 2013 Oct 22. Erratum in: Leukemia. 2015
Dec;29(12):2452. PubMed PMID: 24150217; PubMed Central PMCID: PMC4017258.


61: Giagounidis A, Mufti GJ, Fenaux P, Germing U, List A, MacBeth KJ.
Lenalidomide as a disease-modifying agent in patients with del(5q)
myelodysplastic syndromes: linking mechanism of action to clinical outcomes. Ann
Hematol. 2014 Jan;93(1):1-11. doi: 10.1007/s00277-013-1863-5. Epub 2013 Sep 10.
Review. PubMed PMID: 24018623; PubMed Central PMCID: PMC3889654.


62: Pellagatti A, Benner A, Mills KI, Cazzola M, Giagounidis A, Perry J,
Malcovati L, Della Porta MG, Jädersten M, Verma A, McDonald EJ, Killick S,
Hellström-Lindberg E, Bullinger L, Wainscoat JS, Boultwood J. Identification of
gene expression-based prognostic markers in the hematopoietic stem cells of
patients with myelodysplastic syndromes. J Clin Oncol. 2013 Oct 1;31(28):3557-64.
doi: 10.1200/JCO.2012.45.5626. Epub 2013 Sep 3. PubMed PMID: 24002510.


63: Rodeghiero F, Stasi R, Giagounidis A, Viallard JF, Godeau B, Pabinger I,
Cines D, Liebman H, Wang X, Woodard P. Long-term safety and tolerability of
romiplostim in patients with primary immune thrombocytopenia: a pooled analysis
of 13 clinical trials. Eur J Haematol. 2013 Nov;91(5):423-36. doi:
10.1111/ejh.12181. Epub 2013 Sep 17. PubMed PMID: 23927437.


64: Serve H, Krug U, Wagner R, Sauerland MC, Heinecke A, Brunnberg U, Schaich M,
Ottmann O, Duyster J, Wandt H, Fischer T, Giagounidis A, Neubauer A, Reichle A,
Aulitzky W, Noppeney R, Blau I, Kunzmann V, Stuhlmann R, Krämer A, Kreuzer KA,
Brandts C, Steffen B, Thiede C, Müller-Tidow C, Ehninger G, Berdel WE. Sorafenib
in combination with intensive chemotherapy in elderly patients with acute myeloid
leukemia: results from a randomized, placebo-controlled trial. J Clin Oncol. 2013
Sep 1;31(25):3110-8. doi: 10.1200/JCO.2012.46.4990. Epub 2013 Jul 29. PubMed
PMID: 23897964.


65: Fernandez-Mercado M, Burns A, Pellagatti A, Giagounidis A, Germing U, Agirre
X, Prosper F, Aul C, Killick S, Wainscoat JS, Schuh A, Boultwood J. Targeted
re-sequencing analysis of 25 genes commonly mutated in myeloid disorders in
del(5q) myelodysplastic syndromes. Haematologica. 2013 Dec;98(12):1856-64. doi:
10.3324/haematol.2013.086686. Epub 2013 Jul 5. PubMed PMID: 23831921; PubMed
Central PMCID: PMC3856960.


66: Schanz J, Tüchler H, Solé F, Mallo M, Luño E, Cervera J, Grau J, Hildebrandt
B, Slovak ML, Ohyashiki K, Steidl C, Fonatsch C, Pfeilstöcker M, Nösslinger T,
Valent P, Giagounidis A, Aul C, Lübbert M, Stauder R, Krieger O, Le Beau MM,
Bennett JM, Greenberg P, Germing U, Haase D. Monosomal karyotype in MDS:
explaining the poor prognosis? Leukemia. 2013 Oct;27(10):1988-95. doi:
10.1038/leu.2013.187. Epub 2013 Jun 21. PubMed PMID: 23787396.


67: Giagounidis A. [Myelodysplastic syndromes]. Internist (Berl). 2013
Jun;54(6):699-708. doi: 10.1007/s00108-012-3214-3. German. PubMed PMID: 23657619.


68: Braulke F, Jung K, Schanz J, Götze K, Müller-Thomas C, Platzbecker U, Germing
U, Brümmendorf TH, Bug G, Ottmann O, Giagounidis AA, Stadler M, Hofmann WK,
Schafhausen P, Lübbert M, Schlenk RF, Blau IW, Ganster C, Pfeiffer S, Shirneshan
K, Metz M, Detken S, Seraphin J, Jentsch-Ullrich K, Böhme A, Schmidt B, Trümper
L, Haase D. Molecular cytogenetic monitoring from CD34+ peripheral blood cells in
myelodysplastic syndromes: first results from a prospective multicenter German
diagnostic study. Leuk Res. 2013 Aug;37(8):900-6. doi:
10.1016/j.leukres.2013.03.019. Epub 2013 Apr 25. PubMed PMID: 23623559.


69: Kantarjian HM, Martinelli G, Jabbour EJ, Quintás-Cardama A, Ando K, Bay JO,
Wei A, Gröpper S, Papayannidis C, Owen K, Pike L, Schmitt N, Stockman PK,
Giagounidis A; SPARK-AML1 Investigators. Stage I of a phase 2 study assessing the
efficacy, safety, and tolerability of barasertib (AZD1152) versus low-dose
cytosine arabinoside in elderly patients with acute myeloid leukemia. Cancer.
2013 Jul 15;119(14):2611-9. doi: 10.1002/cncr.28113. Epub 2013 Apr 19. PubMed
PMID: 23605952; PubMed Central PMCID: PMC4132839.


70: Platzbecker U, Braulke F, Kündgen A, Götze K, Bug G, Schönefeldt C,
Shirneshan K, Röllig C, Bornhäuser M, Naumann R, Neesen J, Giagounidis A, Hofmann
WK, Ehninger G, Germing U, Haase D, Wermke M. Sequential combination of
azacitidine and lenalidomide in del(5q) higher-risk myelodysplastic syndromes or
acute myeloid leukemia: a phase I study. Leukemia. 2013 Jun;27(6):1403-7. doi:
10.1038/leu.2013.26. Epub 2013 Jan 28. PubMed PMID: 23354011; PubMed Central
PMCID: PMC3677141.


71: Yip BH, Vuppusetty C, Attwood M, Giagounidis A, Germing U, Lamikanra AA,
Roberts DJ, Maciejewski JP, Vandenberghe P, Mecucci C, Wainscoat JS, Pellagatti
A, Boultwood J. Activation of the mTOR signaling pathway by L-leucine in 5q-
syndrome and other RPS14-deficient erythroblasts. Leukemia. 2013
Aug;27(8):1760-3. doi: 10.1038/leu.2013.20. Epub 2013 Jan 22. PubMed PMID:
23337929.


72: Schroeder T, Czibere A, Platzbecker U, Bug G, Uharek L, Luft T, Giagounidis
A, Zohren F, Bruns I, Wolschke C, Rieger K, Fenk R, Germing U, Haas R, Kröger N,
Kobbe G. Azacitidine and donor lymphocyte infusions as first salvage therapy for
relapse of AML or MDS after allogeneic stem cell transplantation. Leukemia. 2013
Jun;27(6):1229-35. doi: 10.1038/leu.2013.7. Epub 2013 Jan 14. PubMed PMID:
23314834.


73: Kuendgen A, Lauseker M, List AF, Fenaux P, Giagounidis AA, Brandenburg NA,
Backstrom J, Glasmacher A, Hasford J, Germing U; International Working Group on
MDS with del(5q). Lenalidomide does not increase AML progression risk in RBC
transfusion-dependent patients with Low- or Intermediate-1-risk MDS with del(5q):
a comparative analysis. Leukemia. 2013 Apr;27(5):1072-9. doi:
10.1038/leu.2012.369. Epub 2012 Dec 21. PubMed PMID: 23257782; PubMed Central
PMCID: PMC3650492.


74: Schmitz N, Nickelsen M, Ziepert M, Haenel M, Borchmann P, Schmidt C, Viardot
A, Bentz M, Peter N, Ehninger G, Doelken G, Ruebe C, Truemper L, Rosenwald A,
Pfreundschuh M, Loeffler M, Glass B; German High-Grade Lymphoma Study Group
(DSHNHL). Conventional chemotherapy (CHOEP-14) with rituximab or high-dose
chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with
aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL
2002-1). Lancet Oncol. 2012 Dec;13(12):1250-9. doi:
10.1016/S1470-2045(12)70481-3. Epub 2012 Nov 16. PubMed PMID: 23168367.


75: Maassen A, Strupp C, Giagounidis A, Kuendgen A, Nachtkamp K, Hildebrandt B,
Gattermann N, Aul C, Haas R, Germing U. Validation and proposals for a refinement
of the WHO 2008 classification of myelodysplastic syndromes without excess of
blasts. Leuk Res. 2013 Jan;37(1):64-70. doi: 10.1016/j.leukres.2012.09.021. Epub
2012 Oct 31. PubMed PMID: 23122806.


76: Al-Jafar H, Giagounidis A, El-Rashaid K, Al-Ali M, Hakim AA. Use of
romiplostim in a hemodialysis patient with primary immune thrombocytopenia. Ann
Pharmacother. 2012 Nov;46(11):e31. doi: 10.1345/aph.1R134. Epub 2012 Oct 31.
PubMed PMID: 23115229.


77: Giagounidis AA. Lenalidomide for del(5q) and non-del(5q) myelodysplastic
syndromes. Semin Hematol. 2012 Oct;49(4):312-22. doi:
10.1053/j.seminhematol.2012.07.001. Review. PubMed PMID: 23079061.


78: Giagounidis A. Introduction: application of new therapies to myelodysplastic
syndrome. Semin Hematol. 2012 Oct;49(4):285-6. doi:
10.1053/j.seminhematol.2012.09.001. PubMed PMID: 23079057.


79: Nolte F, Höchsmann B, Giagounidis A, Lübbert M, Platzbecker U, Haase D, Lück
A, Gattermann N, Taupitz M, Baier M, Leismann O, Junkes A, Schumann C, Hofmann
WK, Schrezenmeier H. Results from a 1-year, open-label, single arm, multi-center
trial evaluating the efficacy and safety of oral Deferasirox in patients
diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and
transfusion-dependent iron overload. Ann Hematol. 2013 Jan;92(2):191-8. doi:
10.1007/s00277-012-1594-z. Epub 2012 Oct 17. PubMed PMID: 23073603.


80: Robak T, Windyga J, Trelinski J, von Depka Prondzinski M, Giagounidis A,
Doyen C, Janssens A, Alvarez-Román MT, Jarque I, Loscertales J, Rus GP, Hellmann
A, Jêdrzejczak WW, Kuliczkowski K, Golubovic LM, Celeketic D, Cucuianu A,
Gheorghita E, Lazaroiu M, Shpilberg O, Attias D, Karyagina E, Svetlana K,
Vilchevska K, Cooper N, Talks K, Prabhu M, Sripada P, Bharadwaj TP, Næsted H,
Skartved NJ, Frandsen TP, Flensburg MF, Andersen PS, Petersen J. Rozrolimupab, a
mixture of 25 recombinant human monoclonal RhD antibodies, in the treatment of
primary immune thrombocytopenia. Blood. 2012 Nov 1;120(18):3670-6. doi:
10.1182/blood-2012-06-438804. Epub 2012 Aug 20. PubMed PMID: 22915649.


81: Deschler B, Ihorst G, Platzbecker U, Germing U, März E, de Figuerido M,
Fritzsche K, Haas P, Salih HR, Giagounidis A, Selleslag D, Labar B, de Witte T,
Wijermans P, Lübbert M. Parameters detected by geriatric and quality of life
assessment in 195 older patients with myelodysplastic syndromes and acute myeloid
leukemia are highly predictive for outcome. Haematologica. 2013 Feb;98(2):208-16.
doi: 10.3324/haematol.2012.067892. Epub 2012 Aug 8. PubMed PMID: 22875615; PubMed
Central PMCID: PMC3561427.


82: Stasi R, Murali M, Michel M, Viallard JF, Giagounidis A, Janssens A, Legg J,
Deuson R, Danese MD. Evaluation of bleeding-related episodes in patients with
immune thrombocytopenia (ITP) receiving romiplostim or medical standard of care.
Int J Hematol. 2012 Jul;96(1):26-33. doi: 10.1007/s12185-012-1088-8. Epub 2012
May 5. PubMed PMID: 22562409.


83: Metzelder SK, Schroeder T, Finck A, Scholl S, Fey M, Götze K, Linn YC, Kröger
M, Reiter A, Salih HR, Heinicke T, Stuhlmann R, Müller L, Giagounidis A, Meyer
RG, Brugger W, Vöhringer M, Dreger P, Mori M, Basara N, Schäfer-Eckart K,
Schultheis B, Baldus C, Neubauer A, Burchert A. High activity of sorafenib in
FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to
induce sustained responses. Leukemia. 2012 Nov;26(11):2353-9. doi:
10.1038/leu.2012.105. Epub 2012 Apr 16. PubMed PMID: 22504140.


84: Kuter DJ, Mathias SD, Rummel M, Mandanas R, Giagounidis AA, Wang X, Deuson
RR. Health-related quality of life in nonsplenectomized immune thrombocytopenia
patients receiving romiplostim or medical standard of care. Am J Hematol. 2012
May;87(5):558-61. doi: 10.1002/ajh.23163. Epub 2012 Mar 28. PubMed PMID:
22460421.


85: Yip BH, Pellagatti A, Vuppusetty C, Giagounidis A, Germing U, Lamikanra AA,
Roberts DJ, Fernandez-Mercado M, McDonald EJ, Killick S, Wainscoat JS, Boultwood
J. Effects of L-leucine in 5q- syndrome and other RPS14-deficient erythroblasts.
Leukemia. 2012 Sep;26(9):2154-8. doi: 10.1038/leu.2012.82. Epub 2012 Mar 20.
PubMed PMID: 22430631.


86: Germing U, Strupp C, Giagounidis A, Haas R, Gattermann N, Starke C, Aul C.
Evaluation of dysplasia through detailed cytomorphology in 3156 patients from the
Düsseldorf Registry on myelodysplastic syndromes. Leuk Res. 2012
Jun;36(6):727-34. doi: 10.1016/j.leukres.2012.02.014. Epub 2012 Mar 13. PubMed
PMID: 22421409.


87: Dufour A, Schneider F, Hoster E, Benthaus T, Ksienzyk B, Schneider S, Kakadia
PM, Sauerland MC, Berdel WE, Büchner T, Wörmann B, Braess J, Subklewe M,
Hiddemann W, Bohlander SK, Spiekermann K; AML CG study group. Monoallelic CEBPA
mutations in normal karyotype acute myeloid leukemia: independent favorable
prognostic factor within NPM1 mutated patients. Ann Hematol. 2012
Jul;91(7):1051-63. doi: 10.1007/s00277-012-1423-4. Epub 2012 Feb 24. PubMed PMID:
22362118.


88: Schanz J, Tüchler H, Solé F, Mallo M, Luño E, Cervera J, Granada I,
Hildebrandt B, Slovak ML, Ohyashiki K, Steidl C, Fonatsch C, Pfeilstöcker M,
Nösslinger T, Valent P, Giagounidis A, Aul C, Lübbert M, Stauder R, Krieger O,
Garcia-Manero G, Faderl S, Pierce S, Le Beau MM, Bennett JM, Greenberg P, Germing
U, Haase D. New comprehensive cytogenetic scoring system for primary
myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS
derived from an international database merge. J Clin Oncol. 2012 Mar
10;30(8):820-9. doi: 10.1200/JCO.2011.35.6394. Epub 2012 Feb 13. PubMed PMID:
22331955; PubMed Central PMCID: PMC4874200.


89: Germing U, Lauseker M, Hildebrandt B, Symeonidis A, Cermak J, Fenaux P,
Kelaidi C, Pfeilstöcker M, Nösslinger T, Sekeres M, Maciejewski J, Haase D,
Schanz J, Seymour J, Kenealy M, Weide R, Lübbert M, Platzbecker U, Valent P,
Götze K, Stauder R, Blum S, Kreuzer KA, Schlenk R, Ganser A, Hofmann WK, Aul C,
Krieger O, Kündgen A, Haas R, Hasford J, Giagounidis A. Survival, prognostic
factors and rates of leukemic transformation in 381 untreated patients with MDS
and del(5q): a multicenter study. Leukemia. 2012 Jun;26(6):1286-92. doi:
10.1038/leu.2011.391. Epub 2012 Jan 13. PubMed PMID: 22289990.


90: Gröpper S, Althaus K, Najm J, Haase S, Aul C, Greinacher A, Giagounidis A. A
patient with Fechtner syndrome successfully treated with romiplostim. Thromb
Haemost. 2012 Mar;107(3):590-1. doi: 10.1160/TH11-07-0474. Epub 2012 Jan 25.
PubMed PMID: 22273764.


91: Pfeifer H, Lange T, Wystub S, Wassmann B, Maier J, Binckebanck A, Giagounidis
A, Stelljes M, Schmalzing M, Dührsen U, Wunderle L, Serve H, Brück P, Schmidt A,
Hoelzer D, Ottmann OG. Prevalence and dynamics of bcr-abl kinase domain mutations
during imatinib treatment differ in patients with newly diagnosed and recurrent
bcr-abl positive acute lymphoblastic leukemia. Leukemia. 2012 Jul;26(7):1475-81.
doi: 10.1038/leu.2012.5. Epub 2012 Jan 9. PubMed PMID: 22230800.


92: Asemissen AM, Giagounidis A. If it ain't broke, don't fix it! Haematologica.
2011 Nov;96(11):e44. doi: 10.3324/haematol.2011.050872. PubMed PMID: 22058282;
PubMed Central PMCID: PMC3208670.


93: Giagounidis AA, Kulasekararaj A, Germing U, Radkowski R, Haase S, Petersen P,
Göhring G, Büsche G, Aul C, Mufti GJ, Platzbecker U. Long-term transfusion
independence in del(5q) MDS patients who discontinue lenalidomide. Leukemia. 2012
Apr;26(4):855-8. doi: 10.1038/leu.2011.268. Epub 2011 Sep 30. PubMed PMID:
21960245.


94: Göhring G, Lange K, Hofmann W, Nielsen KV, Hellström-Lindberg E, Roy L,
Morgan M, Kreipe H, Büsche G, Giagounidis A, Schlegelberger B. Telomere
shortening, clonal evolution and disease progression in myelodysplastic syndrome
patients with 5q deletion treated with lenalidomide. Leukemia. 2012
Feb;26(2):356-8. doi: 10.1038/leu.2011.193. Epub 2011 Jul 29. PubMed PMID:
21799512.


95: Fenaux P, Giagounidis A, Selleslag D, Beyne-Rauzy O, Mufti G, Mittelman M,
Muus P, Te Boekhorst P, Sanz G, Del Cañizo C, Guerci-Bresler A, Nilsson L,
Platzbecker U, Lübbert M, Quesnel B, Cazzola M, Ganser A, Bowen D, Schlegelberger
B, Aul C, Knight R, Francis J, Fu T, Hellström-Lindberg E; MDS-004 Lenalidomide
del5q Study Group. A randomized phase 3 study of lenalidomide versus placebo in
RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic
syndromes with del5q. Blood. 2011 Oct 6;118(14):3765-76. doi:
10.1182/blood-2011-01-330126. Epub 2011 Jul 13. PubMed PMID: 21753188.


96: Schimmer AD, Herr W, Hänel M, Borthakur G, Frankel A, Horst HA, Martin S,
Kassis J, Desjardins P, Seiter K, Fiedler W, Noppeney R, Giagounidis A, Jacob C,
Jolivet J, Tallman MS, Koschmieder S. Addition of AEG35156 XIAP antisense
oligonucleotide in reinduction chemotherapy does not improve remission rates in
patients with primary refractory acute myeloid leukemia in a randomized phase II
study. Clin Lymphoma Myeloma Leuk. 2011 Oct;11(5):433-8. doi:
10.1016/j.clml.2011.03.033. Epub 2011 May 5. PubMed PMID: 21729686.


97: Schanz J, Steidl C, Fonatsch C, Pfeilstöcker M, Nösslinger T, Tuechler H,
Valent P, Hildebrandt B, Giagounidis A, Aul C, Lübbert M, Stauder R, Krieger O,
Garcia-Manero G, Kantarjian H, Germing U, Haase D, Estey E. Coalesced
multicentric analysis of 2,351 patients with myelodysplastic syndromes indicates
an underestimation of poor-risk cytogenetics of myelodysplastic syndromes in the
international prognostic scoring system. J Clin Oncol. 2011 May
20;29(15):1963-70. doi: 10.1200/JCO.2010.28.3978. Epub 2011 Apr 25. PubMed PMID:
21519021; PubMed Central PMCID: PMC4874202.


98: Pellagatti A, Cazzola M, Giagounidis A, Perry J, Malcovati L, Della Porta MG,
Jädersten M, Killick S, Vyas P, Hellström-Lindberg E, Wainscoat JS, Boultwood J.
Marked down-regulation of nucleophosmin-1 is associated with advanced del(5q)
myelodysplastic syndrome. Br J Haematol. 2011 Oct;155(2):272-4. doi:
10.1111/j.1365-2141.2011.08672.x. Epub 2011 Apr 15. PubMed PMID: 21492127.


99: Lübbert M, Suciu S, Baila L, Rüter BH, Platzbecker U, Giagounidis A,
Selleslag D, Labar B, Germing U, Salih HR, Beeldens F, Muus P, Pflüger KH, Coens
C, Hagemeijer A, Eckart Schaefer H, Ganser A, Aul C, de Witte T, Wijermans PW.
Low-dose decitabine versus best supportive care in elderly patients with
intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for
intensive chemotherapy: final results of the randomized phase III study of the
European Organisation for Research and Treatment of Cancer Leukemia Group and the
German MDS Study Group. J Clin Oncol. 2011 May 20;29(15):1987-96. doi:
10.1200/JCO.2010.30.9245. Epub 2011 Apr 11. PubMed PMID: 21483003.


100: Giagounidis A, Leto di Priolo S, Ille S, Fenaux P. A European survey on the
detection and management of iron overload in transfusion-dependent patients with
MDS. Ann Hematol. 2011 Jun;90(6):667-73. doi: 10.1007/s00277-011-1181-8. Epub
2011 Feb 16. PubMed PMID: 21327403; PubMed Central PMCID: PMC3087870.


101: Straka C, Sandherr M, Salwender H, Wandt H, Metzner B, Hübel K, Silling G,
Hentrich M, Franke D, Schwerdtfeger R, Freund M, Sezer O, Giagounidis A, Ehninger
G, Grimminger W, Engert A, Schlimok G, Scheid C, Hellmann P, Heinisch H, Einsele
H, Hinke A, Emmerich B. Testing G-CSF responsiveness predicts the individual
susceptibility to infection and consecutive treatment in recipients of high-dose
chemotherapy. Blood. 2011 Feb 17;117(7):2121-8. doi:
10.1182/blood-2010-06-290080. Epub 2010 Dec 16. PubMed PMID: 21163927.


102: Passweg JR, Giagounidis AA, Simcock M, Aul C, Dobbelstein C, Stadler M,
Ossenkoppele G, Hofmann WK, Schilling K, Tichelli A, Ganser A. Immunosuppressive
therapy for patients with myelodysplastic syndrome: a prospective randomized
multicenter phase III trial comparing antithymocyte globulin plus cyclosporine
with best supportive care--SAKK 33/99. J Clin Oncol. 2011 Jan 20;29(3):303-9.
doi: 10.1200/JCO.2010.31.2686. Epub 2010 Dec 13. PubMed PMID: 21149672.


103: Krug U, Röllig C, Koschmieder A, Heinecke A, Sauerland MC, Schaich M, Thiede
C, Kramer M, Braess J, Spiekermann K, Haferlach T, Haferlach C, Koschmieder S,
Rohde C, Serve H, Wörmann B, Hiddemann W, Ehninger G, Berdel WE, Büchner T,
Müller-Tidow C; German Acute Myeloid Leukaemia Cooperative Group; Study Alliance
Leukemia Investigators. Complete remission and early death after intensive
chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a
web-based application for prediction of outcomes. Lancet. 2010 Dec
11;376(9757):2000-8. doi: 10.1016/S0140-6736(10)62105-8. Epub 2010 Dec 3. PubMed
PMID: 21131036.


104: Göhring G, Giagounidis A, Büsche G, Hofmann W, Kreipe HH, Fenaux P,
Hellström-Lindberg E, Schlegelberger B. Cytogenetic follow-up by karyotyping and
fluorescence in situ hybridization: implications for monitoring patients with
myelodysplastic syndrome and deletion 5q treated with lenalidomide.
Haematologica. 2011 Feb;96(2):319-22. doi: 10.3324/haematol.2010.026658. Epub
2010 Nov 25. PubMed PMID: 21109690; PubMed Central PMCID: PMC3031702.


105: Russwurm G, Heinsch M, Radkowski R, Erlemann R, Aul C, Haase S, Giagounidis
A. Dasatinib induces complete remission in a patient with primary cerebral
involvement of B-cell chronic lymphocytic leukemia failing chemotherapy. Blood.
2010 Oct 7;116(14):2617-8. doi: 10.1182/blood-2010-04-279786. PubMed PMID:
20930084.


106: Mallo M, Cervera J, Schanz J, Such E, García-Manero G, Luño E, Steidl C,
Espinet B, Vallespí T, Germing U, Blum S, Ohyashiki K, Grau J, Pfeilstöcker M,
Hernández JM, Noesslinger T, Giagounidis A, Aul C, Calasanz MJ, Martín ML, Valent
P, Collado R, Haferlach C, Fonatsch C, Lübbert M, Stauder R, Hildebrandt B,
Krieger O, Pedro C, Arenillas L, Sanz MÁ, Valencia A, Florensa L, Sanz GF, Haase
D, Solé F. Impact of adjunct cytogenetic abnormalities for prognostic
stratification in patients with myelodysplastic syndrome and deletion 5q.
Leukemia. 2011 Jan;25(1):110-20. doi: 10.1038/leu.2010.231. Epub 2010 Sep 30.
PubMed PMID: 20882045.


107: Chen C, Bowen DT, Giagounidis AA, Schlegelberger B, Haase S, Wright EG.
Identification of disease- and therapy-associated proteome changes in the sera of
patients with myelodysplastic syndromes and del(5q). Leukemia. 2010
Nov;24(11):1875-84. doi: 10.1038/leu.2010.182. Epub 2010 Aug 26. PubMed PMID:
20739954.


108: Götze K, Platzbecker U, Giagounidis A, Haase D, Lübbert M, Aul C, Ganser A,
Germing U, Hofmann WK. Azacitidine for treatment of patients with myelodysplastic
syndromes (MDS): practical recommendations of the German MDS Study Group. Ann
Hematol. 2010 Sep;89(9):841-50. doi: 10.1007/s00277-010-1015-0. Epub 2010 Jun 22.
Review. PubMed PMID: 20567826.


109: Matzdorff A, Giagounidis A, Greinacher A, Hiller E, Kiefel V,
Müller-Beissenhirtz H, Ostermann H, Rummel M, Sachs UJ, Salama A. [Diagnosis and
therapy of autoimmune thrombocytopenia. Recommendations of a joint Expert Group
of DGHO, DGTI, DTH]. Onkologie. 2010;33 Suppl 3:2-20. doi: 10.1159/000290758.
Epub 2010 Apr 23. German. PubMed PMID: 20484949.


110: Pellagatti A, Marafioti T, Paterson JC, Barlow JL, Drynan LF, Giagounidis A,
Pileri SA, Cazzola M, McKenzie AN, Wainscoat JS, Boultwood J. Induction of p53
and up-regulation of the p53 pathway in the human 5q- syndrome. Blood. 2010 Apr
1;115(13):2721-3. doi: 10.1182/blood-2009-12-259705. PubMed PMID: 20360478.


111: Pellagatti A, Cazzola M, Giagounidis A, Perry J, Malcovati L, Della Porta
MG, Jädersten M, Killick S, Verma A, Norbury CJ, Hellström-Lindberg E, Wainscoat
JS, Boultwood J. Deregulated gene expression pathways in myelodysplastic syndrome
hematopoietic stem cells. Leukemia. 2010 Apr;24(4):756-64. doi:
10.1038/leu.2010.31. Epub 2010 Mar 11. PubMed PMID: 20220779.


112: Boultwood J, Perry J, Pellagatti A, Fernandez-Mercado M,
Fernandez-Santamaria C, Calasanz MJ, Larrayoz MJ, Garcia-Delgado M, Giagounidis
A, Malcovati L, Della Porta MG, Jädersten M, Killick S, Hellström-Lindberg E,
Cazzola M, Wainscoat JS. Frequent mutation of the polycomb-associated gene ASXL1
in the myelodysplastic syndromes and in acute myeloid leukemia. Leukemia. 2010
May;24(5):1062-5. doi: 10.1038/leu.2010.20. Epub 2010 Feb 25. PubMed PMID:
20182461.


113: Aul C, Giagounidis A, Germing U. [Myelodysplastic syndromes]. Internist
(Berl). 2010 Feb;51(2):169-82; quiz 183-4. doi: 10.1007/s00108-009-2552-2.
German. PubMed PMID: 20082063.


114: Göhring G, Giagounidis A, Büsche G, Kreipe HH, Zimmermann M,
Hellström-Lindberg E, Aul C, Schlegelberger B. Patients with del(5q) MDS who fail
to achieve sustained erythroid or cytogenetic remission after treatment with
lenalidomide have an increased risk for clonal evolution and AML progression. Ann
Hematol. 2010 Apr;89(4):365-74. doi: 10.1007/s00277-009-0846-z. Epub 2009 Oct 24.
PubMed PMID: 19855965.


115: Viscoli C, Herbrecht R, Akan H, Baila L, Sonet A, Gallamini A, Giagounidis
A, Marchetti O, Martino R, Meert L, Paesmans M, Ameye L, Shivaprakash M, Ullmann
AJ, Maertens J; Infectious Disease Group of the EORTC. An EORTC Phase II study of
caspofungin as first-line therapy of invasive aspergillosis in haematological
patients. J Antimicrob Chemother. 2009 Dec;64(6):1274-81. doi:
10.1093/jac/dkp355. Epub 2009 Oct 19. PubMed PMID: 19841031.


116: Lengfelder E, Haferlach C, Saussele S, Haferlach T, Schultheis B, Schnittger
S, Ludwig WD, Staib P, Aul C, Grüneisen A, Kern W, Reichle A, Serve H, Berdel WE,
Braess J, Spiekermann K, Wörmann B, Sauerland MC, Heinecke A, Hiddemann W,
Hehlmann R, Büchner T; German AML Cooperative Group. High dose ara-C in the
treatment of newly diagnosed acute promyelocytic leukemia: long-term results of
the German AMLCG. Leukemia. 2009 Dec;23(12):2248-58. doi: 10.1038/leu.2009.183.
Epub 2009 Sep 10. PubMed PMID: 19741727.


117: Platzbecker U, Aul C, Ehninger G, Giagounidis A. Reduction of 5-azacitidine
induced skin reactions in MDS patients with evening primrose oil. Ann Hematol.
2010 Apr;89(4):427-8. doi: 10.1007/s00277-009-0824-5. Epub 2009 Aug 28. PubMed
PMID: 19714330.


118: Nösslinger T, Tüchler H, Germing U, Sperr WR, Krieger O, Haase D, Lübbert M,
Stauder R, Giagounidis A, Valent P, Pfeilstöcker M. Prognostic impact of age and
gender in 897 untreated patients with primary myelodysplastic syndromes. Ann
Oncol. 2010 Jan;21(1):120-5. doi: 10.1093/annonc/mdp264. Epub 2009 Jul 15. PubMed
PMID: 19605511.


119: Pellagatti A, Marafioti T, Paterson JC, Malcovati L, Della Porta MG,
Jädersten M, Pushkaran B, George TI, Arber DA, Killick S, Giagounidis A,
Hellström-Lindberg E, Cazzola M, Wainscoat JS, Boultwood J. Marked downregulation
of the granulopoiesis regulator LEF1 is associated with disease progression in
the myelodysplastic syndromes. Br J Haematol. 2009 Jun;146(1):86-90. doi:
10.1111/j.1365-2141.2009.07720.x. Epub 2009 May 5. PubMed PMID: 19438482.


120: Giagounidis AA. Myelodysplasia or myelodysplastic syndrome? Leuk Res. 2009
Aug;33(8):1019. doi: 10.1016/j.leukres.2009.02.012. Epub 2009 Mar 20. PubMed
PMID: 19303635.


121: Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis
A, Schoch R, Gattermann N, Sanz G, List A, Gore SD, Seymour JF, Bennett JM, Byrd
J, Backstrom J, Zimmerman L, McKenzie D, Beach C, Silverman LR; International
Vidaza High-Risk MDS Survival Study Group. Efficacy of azacitidine compared with
that of conventional care regimens in the treatment of higher-risk
myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet
Oncol. 2009 Mar;10(3):223-32. doi: 10.1016/S1470-2045(09)70003-8. Epub 2009 Feb
21. PubMed PMID: 19230772; PubMed Central PMCID: PMC4086808.


122: Nachtkamp K, Kündgen A, Strupp C, Giagounidis A, Kobbe G, Gattermann N, Haas
R, Germing U. Impact on survival of different treatments for myelodysplastic
syndromes (MDS). Leuk Res. 2009 Aug;33(8):1024-8. doi:
10.1016/j.leukres.2008.12.019. Epub 2009 Jan 30. PubMed PMID: 19185917.


123: Prall WC, Czibere A, Grall F, Spentzos D, Steidl U, Giagounidis AAN,
Kuendgen A, Otu H, Rong A, Libermann TA, Germing U, Gattermann N, Haas R, Aivado
M. Differential gene expression of bone marrow-derived CD34+ cells is associated
with survival of patients suffering from myelodysplastic syndrome. Int J Hematol.
2009 Mar;89(2):173-187. doi: 10.1007/s12185-008-0242-9. Epub 2009 Jan 20. PubMed
PMID: 19152102.


124: Valent P, Hofmann WK, Büsche G, Sotlar K, Horny HP, Haase D, Haferlach T,
Kern W, Bettelheim P, Baumgartner C, Sperr WR, Nösslinger T, Wimazal F,
Giagounidis AA, Lübbert M, Krieger O, Kolb HJ, Stauder R, Pfeilstöcker M,
Gattermann N, Fonatsch C, Aul C, Germing U. Meeting report: Vienna 2008 Workshop
of the German-Austrian Working Group for Studying Prognostic Factors in
Myelodysplastic Syndromes. Ann Hematol. 2009 Jul;88(7):607-11. doi:
10.1007/s00277-008-0673-7. Epub 2009 Jan 16. PubMed PMID: 19148644.


125: Sekeres MA, Maciejewski JP, Giagounidis AA, Wride K, Knight R, Raza A, List
AF. Relationship of treatment-related cytopenias and response to lenalidomide in
patients with lower-risk myelodysplastic syndromes. J Clin Oncol. 2008 Dec
20;26(36):5943-9. doi: 10.1200/JCO.2007.15.5770. Epub 2008 Nov 17. PubMed PMID:
19018091; PubMed Central PMCID: PMC2645116.


126: Bennett JM; MDS Foundation's Working Group on Transfusional Iron Overload.
Consensus statement on iron overload in myelodysplastic syndromes. Am J Hematol.
2008 Nov;83(11):858-61. doi: 10.1002/ajh.21269. PubMed PMID: 18767130.


127: Wang L, Fidler C, Nadig N, Giagounidis A, Della Porta MG, Malcovati L,
Killick S, Gattermann N, Aul C, Boultwood J, Wainscoat JS. Genome-wide analysis
of copy number changes and loss of heterozygosity in myelodysplastic syndrome
with del(5q) using high-density single nucleotide polymorphism arrays.
Haematologica. 2008 Jul;93(7):994-1000. doi: 10.3324/haematol.12603. Epub 2008
May 27. PubMed PMID: 18508791.


128: Pellagatti A, Hellström-Lindberg E, Giagounidis A, Perry J, Malcovati L,
Della Porta MG, Jädersten M, Killick S, Fidler C, Cazzola M, Wainscoat JS,
Boultwood J. Haploinsufficiency of RPS14 in 5q- syndrome is associated with
deregulation of ribosomal- and translation-related genes. Br J Haematol. 2008
Jul;142(1):57-64. doi: 10.1111/j.1365-2141.2008.07178.x. Epub 2008 May 8. Erratum
in: Br J Haematol. 2009 Feb;144(3):455. PubMed PMID: 18477045; PubMed Central
PMCID: PMC2440427.


129: Giagounidis AA, Germing U, Haase S, Aul C. Lenalidomide: a brief review of
its therapeutic potential in myelodysplastic syndromes. Ther Clin Risk Manag.
2007 Aug;3(4):553-62. PubMed PMID: 18472976; PubMed Central PMCID: PMC2374932.


130: Boultwood J, Pellagatti A, Nikpour M, Pushkaran B, Fidler C, Cattan H,
Littlewood TJ, Malcovati L, Della Porta MG, Jädersten M, Killick S, Giagounidis
A, Bowen D, Hellström-Lindberg E, Cazzola M, Wainscoat JS. The role of the iron
transporter ABCB7 in refractory anemia with ring sideroblasts. PLoS One. 2008 Apr
9;3(4):e1970. doi: 10.1371/journal.pone.0001970. PubMed PMID: 18398482; PubMed
Central PMCID: PMC2276313.


131: Giagounidis AA, Aul C. The 5q- syndrome. Cancer Treat Res. 2008;142:133-48.
Review. PubMed PMID: 18283785.


132: Giagounidis A, Fenaux P, Mufti GJ, Muus P,